FAB.L
Fusion Antibodies plc [FAB.L] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
FAB.L Stock Summary
In the News
FAB.L Financial details
Company Rating
Sell
Market Cap
3.67M
Income
-4.57M
Revenue
5.8M
Book val./share
0.03
Cash/share
0.01
Dividend
-
Dividend %
-
Employees
48
Optionable
No
Shortable
Yes
Earnings
07 Dec 2023
P/E
-0.55
Forward P/E
-
PEG
-0.02
P/S
1.3
P/B
0.99
P/C
375
P/FCF
-1.95
Quick Ratio
1.31
Current Ratio
1.92
Debt / Equity
0.03
LT Debt / Equity
0.02
-
-
EPS (TTM)
-0.15
EPS next Y
-
EPS next Q
-
EPS this Y
115.55%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
11.78%
Revenue last 5Y
5.86%
Revenue Q/Q
-47.88%
EPS Q/Q
-48.68%
-
-
-
-
SMA20
-
SMA50
-20%
SMA100
33.33%
Inst Own
0%
Inst Trans
0%
ROA
-99%
ROE
216%
ROC
-1.89%
Gross Margin
14%
Oper. Margin
-113%
Profit Margin
-103%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.02-50.0
52W High
-92.5%
52W Low
+25%
RSI
45
Rel Volume
0.1
Avg Volume
1.34M
Volume
138.15K
Perf Week
-10.71%
Perf Month
-3.85%
Perf Quarter
-26.9%
Perf Half Y
-36.22%
-
-
-
-
Beta
0.437
-
-
Volatility
0.1%, 0.12%
Prev Close
0%
Price
3.75
Change
0.81%
FAB.L Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-03-31
| Metric | History | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.1 | 0.18 | 0.16 | 0.18 | 0.11 | |
| Net income per share | -0.06 | -0.03 | -0.11 | -0.05 | -0.1 | |
| Operating cash flow per share | -0.05 | -0.01 | -0.05 | -0.01 | -0.07 | |
| Free cash flow per share | -0.11 | -0.01 | -0.06 | -0.02 | -0.07 | |
| Cash per share | 0.09 | 0.07 | 0.11 | 0.08 | 0.01 | |
| Book value per share | 0.24 | 0.22 | 0.19 | 0.14 | 0.04 | |
| Tangible book value per share | 0.24 | 0.22 | 0.19 | 0.14 | 0.04 | |
| Share holders equity per share | 0.24 | 0.22 | 0.19 | 0.14 | 0.04 | |
| Interest debt per share | 0.01 | 0.02 | 0.01 | 0 | 0 | |
| Market cap | 6.3M | 20.99M | 39.97M | 15.57M | 10.02M | |
| Enterprise value | 4.45M | 19.83M | 37.51M | 13.59M | 9.9M | |
| P/E ratio | -4.98 | -30.11 | -13.79 | -12.97 | -3.86 | |
| Price to sales ratio | 2.89 | 5.39 | 9.6 | 3.24 | 3.45 | |
| POCF ratio | -5.73 | -126.43 | -34.73 | -46.75 | -5.71 | |
| PFCF ratio | -2.54 | -76.32 | -26.37 | -26.34 | -5.36 | |
| P/B Ratio | 1.18 | 4.36 | 8.42 | 4.23 | 8.92 | |
| PTB ratio | 1.18 | 4.36 | 8.42 | 4.23 | 8.92 | |
| EV to sales | 2.04 | 5.09 | 9.01 | 2.83 | 3.41 | |
| Enterprise value over EBITDA | -4.18 | -40.3 | -56.41 | -23.39 | -4.02 | |
| EV to operating cash flow | -4.05 | -119.46 | -32.59 | -40.8 | -5.64 | |
| EV to free cash flow | -1.8 | -72.11 | -24.75 | -22.99 | -5.29 | |
| Earnings yield | -0.2 | -0.03 | -0.07 | -0.08 | -0.26 | |
| Free cash flow yield | -0.39 | -0.01 | -0.04 | -0.04 | -0.19 | |
| Debt to equity | 0.03 | 0.08 | 0.05 | 0.02 | 0.07 | |
| Debt to assets | 0.02 | 0.06 | 0.04 | 0.01 | 0.04 | |
| Net debt to EBITDA | 1.73 | 2.35 | 3.69 | 3.41 | 0.05 | |
| Current ratio | 4.15 | 2.83 | 4.72 | 3.54 | 1.92 | |
| Interest coverage | -374.02 | -55.7 | -76.61 | -148 | -708.25 | |
| Income quality | 0.87 | 0.24 | 0.4 | 0.28 | 0.68 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 1.1 | 0.58 | 0.66 | 0.63 | 1.05 | |
| Research and developement to revenue | 0.11 | 0.1 | 0.15 | 0.15 | 0.28 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 1.26 | 0.66 | 0.32 | 0.77 | 0.06 | |
| Capex to revenue | -0.63 | -0.03 | -0.09 | -0.05 | -0.04 | |
| Capex to depreciation | -3.2 | -0.18 | -0.51 | -0.34 | -0.31 | |
| Stock based compensation to revenue | 0.04 | 0.02 | 0 | 0 | 0.01 | |
| Graham number | 0.56 | 0.39 | 0.69 | 0.38 | 0.31 | |
| ROIC | -0.23 | -0.13 | -0.63 | -0.32 | -2.08 | |
| Return on tangible assets | -0.2 | -0.12 | -0.5 | -0.24 | -1.26 | |
| Graham Net | 0.09 | 0.05 | 0.12 | 0.09 | 0.01 | |
| Working capital | 2.51M | 1.81M | 3.71M | 3.07M | 808K | |
| Tangible asset value | 5.35M | 4.81M | 4.75M | 3.68M | 1.12M | |
| Net current asset value | 2.42M | 1.57M | 3.62M | 3.05M | 748K | |
| Invested capital | 0.03 | 0.08 | 0.05 | 0.02 | 0.07 | |
| Average receivables | 794.95K | 1M | 1.23M | 1.59M | 1.3M | |
| Average payables | 371.55K | 438.41K | 379.5K | 405K | 473K | |
| Average inventory | 162.24K | 291.33K | 410K | 532.5K | 562K | |
| Days sales outstanding | 180.51 | 86.68 | 134.87 | 125.34 | 119.91 | |
| Days payables outstanding | 122.34 | 55.22 | 43.98 | 55.19 | 64.91 | |
| Days of inventory on hand | 64.28 | 45.24 | 61.37 | 69.28 | 72.89 | |
| Receivables turnover | 2.02 | 4.21 | 2.71 | 2.91 | 3.04 | |
| Payables turnover | 2.98 | 6.61 | 8.3 | 6.61 | 5.62 | |
| Inventory turnover | 5.68 | 8.07 | 5.95 | 5.27 | 5.01 | |
| ROE | -0.24 | -0.14 | -0.61 | -0.33 | -2.31 | |
| Capex per share | -0.06 | 0 | -0.01 | -0.01 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q2
| Metric | History | 2021-09-30 | 2022-03-31 | 2022-09-30 | 2023-03-31 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.09 | 0.09 | 0.07 | 0.04 | 0.01 | |
| Net income per share | -0.02 | -0.02 | -0.04 | -0.06 | -0.03 | |
| Operating cash flow per share | -0.02 | 0.01 | -0.03 | -0.04 | -0.03 | |
| Free cash flow per share | -0.03 | 0 | -0.04 | -0.03 | -0.03 | |
| Cash per share | 0.08 | 0.08 | 0.05 | 0.01 | 0.01 | |
| Book value per share | 0.16 | 0.14 | 0.1 | 0.04 | 0.03 | |
| Tangible book value per share | 0.16 | 0.14 | 0.1 | 0.04 | 0.03 | |
| Share holders equity per share | 0.16 | 0.14 | 0.1 | 0.04 | 0.03 | |
| Interest debt per share | 0.01 | 0 | 0.01 | 0 | 0 | |
| Market cap | 32.92M | 15.61M | 13.27M | 10.02M | 2.56M | |
| Enterprise value | 31.09M | 13.63M | 12.4M | 9.9M | 2.12M | |
| P/E ratio | -14.09 | -6.33 | -2.97 | -1.69 | -0.47 | |
| Price to sales ratio | 13.49 | 6.62 | 7.12 | 9.65 | 4.73 | |
| POCF ratio | -64.94 | 89.71 | -17.46 | -10.07 | -1.89 | |
| PFCF ratio | -47.17 | 145.88 | -11.87 | -13.34 | -1.89 | |
| P/B Ratio | 7.75 | 4.24 | 5.16 | 8.92 | 1.76 | |
| PTB ratio | 7.75 | 4.24 | 5.16 | 8.92 | 1.76 | |
| EV to sales | 12.74 | 5.78 | 6.66 | 9.53 | 3.91 | |
| Enterprise value over EBITDA | -96.85 | -48.16 | -12.21 | -6.68 | -1.64 | |
| EV to operating cash flow | -61.32 | 78.33 | -16.32 | -9.95 | -1.57 | |
| EV to free cash flow | -44.54 | 127.37 | -11.09 | -13.18 | -1.57 | |
| Earnings yield | -0.02 | -0.04 | -0.08 | -0.15 | -0.53 | |
| Free cash flow yield | -0.02 | 0.01 | -0.08 | -0.07 | -0.53 | |
| Debt to equity | 0.04 | 0.02 | 0.13 | 0.07 | 0.03 | |
| Debt to assets | 0.03 | 0.01 | 0.08 | 0.04 | 0.02 | |
| Net debt to EBITDA | 5.72 | 7 | 0.85 | 0.08 | 0.34 | |
| Current ratio | 4.09 | 3.54 | 2.84 | 1.92 | 3.26 | |
| Interest coverage | -231.67 | -110 | -180.57 | 0 | -473 | |
| Income quality | 0.87 | -0.28 | 0.68 | 0.67 | 1 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 1.28 | 0 | 2.94 | 0 | |
| Research and developement to revenue | 0.17 | 0.12 | 0.24 | 0.34 | 0.34 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.38 | -0.39 | 0.47 | -0.25 | 0 | |
| Capex to revenue | -0.08 | -0.03 | -0.19 | 0.24 | 0 | |
| Capex to depreciation | -0.51 | -0.18 | -1.44 | 1.97 | 0 | |
| Stock based compensation to revenue | 0 | 0.01 | 0 | 0.03 | 0.03 | |
| Graham number | 0.29 | 0.27 | 0.31 | 0.24 | 0.14 | |
| ROIC | -0.14 | -0.16 | -0.35 | -1.2 | -0.89 | |
| Return on tangible assets | -0.11 | -0.13 | -0.28 | -0.72 | -0.66 | |
| Graham Net | 0.1 | 0.09 | 0.05 | 0.01 | 0.02 | |
| Working capital | 3.35M | 3.07M | 2.1M | 808K | 1.25M | |
| Tangible asset value | 4.25M | 3.68M | 2.57M | 1.12M | 1.45M | |
| Net current asset value | 3.3M | 3.05M | 1.83M | 748K | 1.2M | |
| Invested capital | 0.04 | 0.02 | 0.13 | 0.07 | 0.03 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 0 | 0 | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 69.35 | 62.9 | 71.93 | 82.63 | 132.59 | |
| Days payables outstanding | 53.23 | 69.97 | 63.25 | 63.56 | 64.44 | |
| Days of inventory on hand | 31.36 | 35.84 | 33.03 | 40.59 | 62.88 | |
| Receivables turnover | 1.3 | 1.43 | 1.25 | 1.09 | 0.68 | |
| Payables turnover | 1.69 | 1.29 | 1.42 | 1.42 | 1.4 | |
| Inventory turnover | 2.87 | 2.51 | 2.72 | 2.22 | 1.43 | |
| ROE | -0.14 | -0.17 | -0.43 | -1.32 | -0.93 | |
| Capex per share | -0.01 | 0 | -0.01 | 0.01 | 0 |
FAB.L Frequently Asked Questions
What is Fusion Antibodies plc stock symbol ?
Fusion Antibodies plc is a GB stock and trading under the symbol FAB.L
What is Fusion Antibodies plc stock quote today ?
Fusion Antibodies plc stock price is $3.75 today.
Is Fusion Antibodies plc stock public?
Yes, Fusion Antibodies plc is a publicly traded company.
Company Profile
- Volume Average 1.34M
- Market Capitalization 3.67M
- Employee 48
- CEO Dr. Adrian Robert Kinkaid Ph.D.
- Headquarters Belfast,GB
- IPO Date 2017-12-18
-
Website
https://www.fusionantibodies.com 
Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. It offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. The company serves pharmaceutical, biotech, and diagnostic companies. It has a collaboration partnership with Celonic AG. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.
